Design Therapeutics, Inc. (DSGN) vs Lexicon Pharmaceuticals, Inc. (LXRX)
Design Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($854.3M and $809.3M). Design Therapeutics, Inc. has the higher net margin (0.00% vs −147.4%) and the higher return on invested capital (0.00% vs −96.4%). Across the 16 metrics below, Design Therapeutics, Inc. leads on 9 and Lexicon Pharmaceuticals, Inc. on 7.
Valuation
Profitability
| Metric | DSGN | LXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 99.14% | 65.16% |
| Operating margin | 0.00% | (131.43%) | 0.00% |
| Net margin | 0.00% | (147.38%) | 0.00% |
| Free cash flow margin | 0.00% | (156.71%) | 0.00% |
| Return on equity | (34.13%) | (40.21%) | (57.72%) |
| Return on assets | (32.33%) | (25.70%) | (49.22%) |
| Return on invested capital | 0.00% | (96.36%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack